Literature DB >> 27308601

ETS1 inactivation causes innate drug resistance to EGFR inhibitors.

Osamu Tetsu1, Janyaporn Phuchareon1, David W Eisele1, Frank McCormick2.   

Abstract

Mutations in epidermal growth factor receptor (EGFR) are found in approximately 10% of lung cancers. Treatment with EGFR inhibitors, although promising, has surprisingly resulted in greater than 90% tumor reduction in only 5% of cases, prompting us to investigate the mechanism of innate drug resistance.

Entities:  

Keywords:  BCL2L11 (best known as BIM); ETS1 transcription factor; MAPK1 (best known as ERK2); MAPK3 (best known as ERK1); dual specificity phosphatase 6 (DUSP6); epidermal growth factor receptor (EGFR); innate drug resistance; non-small-cell lung cancer (NSCLC); tyrosine kinase inhibitor (TKI)

Year:  2015        PMID： 27308601      PMCID： PMC4905380          DOI： 10.1080/23723556.2015.1078924

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Authors:  Eric B Haura; Alejandro D Ricart; Timothy G Larson; Philip J Stella; Lyudmila Bazhenova; Vincent A Miller; Roger B Cohen; Peter D Eisenberg; Paulina Selaru; Keith D Wilner; Shirish M Gadgeel
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

3.  Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Authors:  Erin M Tricker; Chunxiao Xu; Sharmeen Uddin; Marzia Capelletti; Dalia Ercan; Atsuko Ogino; Christine A Pratilas; Neal Rosen; Nathanael S Gray; Kwok-Kin Wong; Pasi A Jänne
Journal:  Cancer Discov       Date:  2015-06-02       Impact factor: 39.397

4.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

5.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

Authors:  Frederic Luciano; Arnaud Jacquel; Pascal Colosetti; Magali Herrant; Sebastien Cagnol; Gilles Pages; Patrick Auberger
Journal:  Oncogene       Date:  2003-10-02       Impact factor: 9.867

6.  EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Authors:  Janyaporn Phuchareon; Frank McCormick; David W Eisele; Osamu Tetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

7.  Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Authors:  Dalia Ercan; Chunxiao Xu; Masahiko Yanagita; Calixte S Monast; Christine A Pratilas; Joan Montero; Mohit Butaney; Takeshi Shimamura; Lynette Sholl; Elena V Ivanova; Madhavi Tadi; Andrew Rogers; Claire Repellin; Marzia Capelletti; Ophélia Maertens; Eva M Goetz; Anthony Letai; Levi A Garraway; Matthew J Lazzara; Neal Rosen; Nathanael S Gray; Kwok-Kin Wong; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-09-07       Impact factor: 39.397

8.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Authors:  Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò
Journal:  Lancet Oncol       Date:  2012-11-28       Impact factor: 41.316

9.  MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.

Authors:  Justin M Balko; Brett R Jones; Virginia L Coakley; Esther P Black
Journal:  Cancer Biol Ther       Date:  2009-03-15       Impact factor: 4.742

10.  Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

Authors:  Zhenfeng Zhang; Susumu Kobayashi; Alain C Borczuk; Rom S Leidner; Thomas Laframboise; Alan D Levine; Balazs Halmos
Journal:  Carcinogenesis       Date:  2010-01-22       Impact factor: 4.741
  10 in total
  4 in total

Review 1.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 2.  ETS-targeted therapy: can it substitute for MEK inhibitors?

Authors:  Osamu Tetsu; Frank McCormick
Journal:  Clin Transl Med       Date:  2017-05-02

3.  The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.

Authors:  Oorvashi Roy Puli; Brian P Danysh; Elena McBeath; Deepankar K Sinha; Nguyet M Hoang; Reid T Powell; Heather E Danysh; Maria E Cabanillas; Gilbert J Cote; Marie-Claude Hofmann
Journal:  Neoplasia       Date:  2018-09-25       Impact factor: 5.715

Review 4.  JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.

Authors:  Garima Pandey; Andrew T Kuykendall; Gary W Reuther
Journal:  Blood Cancer J       Date:  2022-01-26       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.